ReviewMolecular biology reports2026
Nanomedicine in precision treatment of gastric cancer: current clinical landscape.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Gastric cancer (GC) remains a leading cause of cancer-related mortality worldwide, with therapeutic efficacy often hindered by late-stage diagnosis, chemoresistance, and the immunosuppressive tumor immune microenvironment (TIME). This review systematically evaluates the current clinical landscape and emerging breakthroughs in nanomedicine-based interventions for GC. We discuss how unique pathological features of the GC microenvironment such as hypoxia, acidity, and dense stroma-are leveraged to design "smart" stimuli-responsive nanoplatforms for precise drug delivery. Furthermore, the review highlights innovative strategies for TIME remodeling, including macrophage repolarization, cGAS-STING pathway activation, and the integration of multimodal therapies like chemo-photodynamic and immunotherapy. Beyond therapeutics, we examine the pivotal role of nanotechnology in advancing early diagnosis through ultrasensitive biosensors and multimodal imaging probes. Clinically, the successful application of nanoparticle albumin-bound (nab)-paclitaxel underscores the potential of nanomedicine to enhance safety and efficacy. By integrating artificial intelligence (AI) and machine learning for patient stratification, nanomedicine is poised to reshape precision oncology in GC. This review concludes that while challenges in clinical translation persist, the development of bio-inspired nanoplatforms offers a promising frontier for improving the prognostic outlook of gastric cancer patients.
Indexed as
Identifiers
42228196What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.